Le Lézard
Classified in: Health
Subject: SVY

Global Precision Medicine Market 2018-2023 - Market Projected to Reach $87.87 Billion


DUBLIN, Sept. 20, 2018 /PRNewswire/ --

The "Precision Medicine Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The precision medicine market is projected to grow at a CAGR of 8.47% to reach US$87.877 billion in 2023 from US$53.966 billion in 2017.

Major factors responsible for the global precision medicine market growth during the next five years are mainly, increasing efforts to characterize genes and rise in demand for personalized treatment. The global precision medicine sales are expected to be further boosted by rapid technological advancements, favorable government initiatives, and advancements in field of cancer biology. However, factors such as threat related to data sharing remains a challenge to market growth.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Major industry players profiled as part of the report are Nordic Bioscience A/S, Nanostring Technologies, Inc., and Laboratory Corporation of America among others.

Segmentation:

By Technology




By Application

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

5. Precision Medicine Market By Technology

6. Precision Medicine Market By Application

7. Precision Medicine Market By Geography

8. Competitive Intelligence

9. Company Profiles

For more information about this report visit

https://www.researchandmarkets.com/research/38zxls/global_precision?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: